Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
EP. 1: Case Impressions: A 73-Year-Old Woman With DTC
EP. 2: Recommendations for Treating Patients With DTC
EP. 3: Systemic Therapy for RAI-Refractory DTC
EP. 4: Lenvatinib Data for RAI-Refractory DTC
EP. 5: Real-World Insight: Lenvatinib for RAI-Refractory DTC
EP. 6: Progress in Treating RAI-Refractory DTC
EP. 7: Higher Dose Cabozantinib Demonstrates Superior Efficacy Over Lower Dose in MTC
The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.
2 Clarke Drive Cranbury, NJ 08512